$84.18
0.090.11%
Last update: 10:02 AM
15 minutes delayed
Comments
Loading...
Biomarin Pharmaceutical
BMRNNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Biomarin Pharmaceutical (NASDAQ:BMRN) Stock, Analyst Ratings, Price Targets, Forecasts
Biomarin Pharmaceutical Inc has a consensus price target of $107.16 based on the ratings of 28 analysts. The high is $185 issued by B of A Securities on July 21, 2023. The low is $70 issued by Wedbush on August 1, 2023. The 3 most-recent analyst ratings were released by Wells Fargo, Baird, and Evercore ISI Group on June 27, 2024, May 17, 2024, and May 14, 2024, respectively. With an average price target of $100 between Wells Fargo, Baird, and Evercore ISI Group, there's an implied 18.79% upside for Biomarin Pharmaceutical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
Baird
Evercore ISI Group
Morgan Stanley
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Biomarin Pharmaceutical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/27/2024 | Buy Now | 36.61% | Wells Fargo | Mohit Bansal | $110 → $115 | Maintains | Overweight | Get Alert |
| 05/17/2024 | Buy Now | -14.47% | Baird | Joel Beatty | $104 → $72 | Downgrade | Outperform → Neutral | Get Alert |
| 05/14/2024 | Buy Now | 34.24% | Evercore ISI Group | Cory Kasimov | → $113 | Initiates | → Outperform | Get Alert |
| 04/26/2024 | Buy Now | 33.05% | Morgan Stanley | Matthew Harrison | $115 → $112 | Maintains | Overweight | Get Alert |
| 04/26/2024 | Buy Now | 5.73% | Canaccord Genuity | Whitney Ijem | $91 → $89 | Maintains | Hold | Get Alert |
| 04/25/2024 | Buy Now | 30.67% | Cantor Fitzgerald | Olivia Brayer | → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 04/25/2024 | Buy Now | 8.1% | Citigroup | David Lebovitz | $94 → $91 | Maintains | Neutral | Get Alert |
| 04/25/2024 | Buy Now | 0.97% | Scotiabank | George Farmer | $83 → $85 | Maintains | Sector Perform | Get Alert |
| 04/25/2024 | Buy Now | 30.67% | Wells Fargo | Mohit Bansal | $100 → $110 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 8.1% | Canaccord Genuity | Whitney Ijem | → $91 | Reiterates | Hold → Hold | Get Alert |
| 02/23/2024 | Buy Now | 27.11% | Piper Sandler | Christopher Raymond | $115 → $107 | Maintains | Overweight | Get Alert |
| 02/23/2024 | Buy Now | 18.79% | Cantor Fitzgerald | Olivia Brayer | → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | Buy Now | 18.79% | RBC Capital | Luca Issi | → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 01/30/2024 | Buy Now | 23.54% | Baird | Joel Beatty | $127 → $104 | Maintains | Outperform | Get Alert |
| 12/21/2023 | Buy Now | 19.98% | Stifel | Paul Matteis | → $101 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2023 | Buy Now | 18.79% | RBC Capital | Luca Issi | $100 → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 11/03/2023 | Buy Now | 18.79% | BMO Capital | Kostas Biliouris | $102 → $100 | Maintains | Outperform | Get Alert |
| 11/02/2023 | Buy Now | 36.61% | Piper Sandler | Christopher Raymond | $125 → $115 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 38.99% | Morgan Stanley | Matthew Harrison | $125 → $117 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 31.86% | Barclays | Gena Wang | $125 → $111 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 18.79% | Cantor Fitzgerald | Olivia Brayer | $120 → $100 | Maintains | Overweight | Get Alert |
| 10/23/2023 | Buy Now | -2.59% | Bernstein | William Pickering | → $82 | Upgrade | Underperform → Market Perform | Get Alert |
| 10/16/2023 | Buy Now | 42.55% | Cantor Fitzgerald | Olivia Brayer | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 09/28/2023 | Buy Now | — | Raymond James | Laura Chico | — | Initiates | → Market Perform | Get Alert |
| 09/25/2023 | Buy Now | 66.31% | Truist Securities | Robyn Karnauskas | → $140 | Reiterates | Buy → Buy | Get Alert |
| 09/18/2023 | Buy Now | 42.55% | UBS | Martin Auster | → $120 | Initiates | → Buy | Get Alert |
| 09/15/2023 | Buy Now | 66.31% | Truist Securities | Robyn Karnauskas | → $140 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | 42.55% | Cantor Fitzgerald | Olivia Brayer | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 09/13/2023 | Buy Now | 30.67% | Guggenheim | Debjit Chattopadhyay | → $110 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 18.79% | RBC Capital | Luca Issi | → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 09/13/2023 | Buy Now | 42.55% | Cantor Fitzgerald | Olivia Brayer | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 08/01/2023 | Buy Now | 48.49% | Morgan Stanley | Matthew Harrison | $129 → $125 | Maintains | Overweight | Get Alert |
| 08/01/2023 | Buy Now | 28.3% | Stifel | Paul Matteis | $118 → $108 | Maintains | Buy | Get Alert |
| 08/01/2023 | Buy Now | -16.84% | Wedbush | Andreas Argyrides | $73 → $70 | Maintains | Neutral | Get Alert |
| 08/01/2023 | Buy Now | 42.55% | Cantor Fitzgerald | Olivia Brayer | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 08/01/2023 | Buy Now | 18.79% | RBC Capital | Luca Issi | → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 07/27/2023 | Buy Now | 12.85% | Scotiabank | George Farmer | → $95 | Initiates | → Sector Perform | Get Alert |
| 07/21/2023 | Buy Now | 119.77% | B of A Securities | Geoff Meacham | $200 → $185 | Maintains | Buy | Get Alert |
| 07/05/2023 | Buy Now | 21.17% | BMO Capital | Kostas Biliouris | → $102 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/03/2023 | Buy Now | 23.54% | Canaccord Genuity | Whitney Ijem | $110 → $104 | Maintains | Hold | Get Alert |
| 06/30/2023 | Buy Now | 14.04% | Citigroup | David Lebowitz | $103 → $96 | Maintains | Neutral | Get Alert |
| 06/30/2023 | Buy Now | 50.87% | Baird | Joel Beatty | → $127 | Reiterates | Outperform → Outperform | Get Alert |
| 06/30/2023 | Buy Now | -13.28% | Wedbush | Andreas Argyrides | $69 → $73 | Maintains | Neutral | Get Alert |
| 06/30/2023 | Buy Now | 66.31% | Truist Securities | Robyn Karnauskas | $125 → $140 | Maintains | Buy | Get Alert |
| 06/14/2023 | Buy Now | 42.55% | Credit Suisse | Tiago Fauth | → $120 | Assumes | → Outperform | Get Alert |
| 04/27/2023 | Buy Now | 22.36% | Citigroup | David Lebowitz | $114 → $103 | Maintains | Neutral | Get Alert |
| 04/27/2023 | Buy Now | 42.55% | Guggenheim | Debjit Chattopadhyay | $125 → $120 | Maintains | Buy | Get Alert |
| 04/27/2023 | Buy Now | 48.49% | Piper Sandler | Christopher Raymond | $128 → $125 | Maintains | Overweight | Get Alert |
| 04/27/2023 | Buy Now | 18.79% | RBC Capital | Luca Issi | → $100 | Reiterates | → Sector Perform | Get Alert |
| 04/27/2023 | Buy Now | -18.03% | Wedbush | Andreas Argyrides | $74 → $69 | Maintains | Neutral | Get Alert |
| 04/27/2023 | Buy Now | 42.55% | Credit Suisse | Tiago Fauth | $122 → $120 | Maintains | Outperform | Get Alert |
| 04/27/2023 | Buy Now | 50.87% | Baird | Joel Beatty | $112 → $127 | Maintains | Outperform | Get Alert |
| 03/21/2023 | Buy Now | -3.78% | Bernstein | William Pickering | → $81 | Initiates | → Underperform | Get Alert |
| 03/07/2023 | Buy Now | 21.17% | BMO Capital | Kostas Biliouris | $107 → $102 | Maintains | Market Perform | Get Alert |
| 02/28/2023 | Buy Now | 48.49% | Guggenheim | Debjit Chattopadhyay | → $125 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 40.18% | Stifel | Paul Matteis | $114 → $118 | Maintains | Buy | Get Alert |
| 02/28/2023 | Buy Now | -12.09% | Wedbush | Andreas Argyrides | $83 → $74 | Maintains | Neutral | Get Alert |
| 02/28/2023 | Buy Now | 33.05% | Canaccord Genuity | Whitney Ijem | $119 → $112 | Maintains | Hold | Get Alert |
| 02/28/2023 | Buy Now | 55.62% | Morgan Stanley | Matthew Harrison | $132 → $131 | Maintains | Overweight | Get Alert |
| 02/28/2023 | Buy Now | 50.87% | Credit Suisse | Tiago Fauth | $110 → $127 | Maintains | Outperform | Get Alert |
| 02/22/2023 | Buy Now | — | Oppenheimer | Leland Gershell | — | Downgrade | Outperform → Perform | Get Alert |
| 02/21/2023 | Buy Now | 37.8% | Citigroup | David Lebowitz | → $116 | Initiates | → Neutral | Get Alert |
| 02/03/2023 | Buy Now | 54.43% | SVB Leerink | Joseph Schwartz | $122 → $130 | Maintains | Outperform | Get Alert |
| 01/30/2023 | Buy Now | 27.11% | BMO Capital | Kostas Biliouris | → $107 | Initiates | → Market Perform | Get Alert |
| 01/24/2023 | Buy Now | 56.81% | Morgan Stanley | Matthew Harrison | $113 → $132 | Maintains | Overweight | Get Alert |
| 01/18/2023 | Buy Now | 41.36% | Canaccord Genuity | Whitney Ijem | → $119 | Initiates | → Hold | Get Alert |
| 01/11/2023 | Buy Now | -1.4% | Wedbush | Andreas Argyrides | $74 → $83 | Maintains | Neutral | Get Alert |
| 11/29/2022 | Buy Now | 42.55% | Jefferies | Akash Tewari | $100 → $120 | Maintains | Buy | Get Alert |
| 10/31/2022 | Buy Now | 30.67% | Oppenheimer | Leland Gershell | $92 → $110 | Upgrade | Perform → Outperform | Get Alert |
| 10/27/2022 | Buy Now | 30.67% | Credit Suisse | Tiago Fauth | $111 → $110 | Maintains | Outperform | Get Alert |
| 10/27/2022 | Buy Now | 34.24% | Morgan Stanley | Matthew Harrison | $111 → $113 | Maintains | Overweight | Get Alert |
| 10/24/2022 | Buy Now | 33.05% | JP Morgan | Jessica Fye | $140 → $112 | Maintains | Overweight | Get Alert |
| 10/13/2022 | Buy Now | 12.85% | RBC Capital | Luca Issi | $90 → $95 | Maintains | Sector Perform | Get Alert |
| 10/13/2022 | Buy Now | 31.86% | Morgan Stanley | Matthew Harrison | $117 → $111 | Maintains | Overweight | Get Alert |
| 08/09/2022 | Buy Now | 52.06% | Piper Sandler | Christopher Raymond | $125 → $128 | Maintains | Overweight | Get Alert |
| 08/04/2022 | Buy Now | 38.99% | Morgan Stanley | Matthew Harrison | $113 → $117 | Maintains | Overweight | Get Alert |
| 08/04/2022 | Buy Now | 44.93% | SVB Leerink | Joseph Schwartz | $115 → $122 | Maintains | Outperform | Get Alert |
| 08/04/2022 | Buy Now | 48.49% | Barclays | Gena Wang | $112 → $125 | Maintains | Overweight | Get Alert |
| 07/13/2022 | Buy Now | 30.67% | Cantor Fitzgerald | Olivia Brayer | → $110 | Initiates | → Overweight | Get Alert |
| 06/13/2022 | Buy Now | -16.84% | Wedbush | Andreas Argyrides | → $70 | Assumes | → Neutral | Get Alert |
| 06/06/2022 | Buy Now | 25.92% | Credit Suisse | Tiago Fauth | $105 → $106 | Maintains | Outperform | Get Alert |
| 04/25/2022 | Buy Now | 34.24% | Morgan Stanley | Matthew Harrison | $96 → $113 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 04/12/2022 | Buy Now | 14.04% | Morgan Stanley | Matthew Harrison | $90 → $96 | Maintains | Equal-Weight | Get Alert |
| 02/24/2022 | Buy Now | 48.49% | Piper Sandler | Christopher Raymond | $121 → $125 | Maintains | Overweight | Get Alert |
| 11/22/2021 | Buy Now | 24.73% | Credit Suisse | Tiago Fauth | — | Maintains | Outperform | Get Alert |
| 11/22/2021 | Buy Now | 6.91% | Morgan Stanley | Matthew Harrison | — | Maintains | Equal-Weight | Get Alert |
| 11/22/2021 | Buy Now | — | William Blair | Tim Lugo | — | Upgrade | Market Perform → Outperform | Get Alert |
| 11/22/2021 | Buy Now | 36.61% | SVB Leerink | Joseph Schwartz | — | Maintains | Outperform | Get Alert |
| 11/15/2021 | Buy Now | 33.05% | SVB Leerink | Joseph Schwartz | — | Maintains | Outperform | Get Alert |
| 10/28/2021 | Buy Now | 18.79% | Credit Suisse | Tiago Fauth | — | Maintains | Outperform | Get Alert |
| 09/09/2021 | Buy Now | 14.04% | Stifel | Paul Matteis | — | Upgrade | Hold → Buy | Get Alert |
| 07/29/2021 | Buy Now | 4.54% | RBC Capital | Kennen MacKay | — | Maintains | Sector Perform | Get Alert |
FAQ
What is the target price for Biomarin Pharmaceutical (BMRN) stock?
The latest price target for Biomarin Pharmaceutical (NASDAQ:BMRN) was reported by Wells Fargo on June 27, 2024. The analyst firm set a price target for $115.00 expecting BMRN to rise to within 12 months (a possible 36.61% upside). 37 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Biomarin Pharmaceutical (BMRN)?
The latest analyst rating for Biomarin Pharmaceutical (NASDAQ:BMRN) was provided by Wells Fargo, and Biomarin Pharmaceutical maintained their overweight rating.
When was the last upgrade for Biomarin Pharmaceutical (BMRN)?
The last upgrade for Biomarin Pharmaceutical Inc happened on October 23, 2023 when Bernstein raised their price target to $82. Bernstein previously had an underperform for Biomarin Pharmaceutical Inc.
When was the last downgrade for Biomarin Pharmaceutical (BMRN)?
The last downgrade for Biomarin Pharmaceutical Inc happened on May 17, 2024 when Baird changed their price target from $104 to $72 for Biomarin Pharmaceutical Inc.
When is the next analyst rating going to be posted or updated for Biomarin Pharmaceutical (BMRN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biomarin Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biomarin Pharmaceutical was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.
Is the Analyst Rating Biomarin Pharmaceutical (BMRN) correct?
While ratings are subjective and will change, the latest Biomarin Pharmaceutical (BMRN) rating was a maintained with a price target of $110.00 to $115.00. The current price Biomarin Pharmaceutical (BMRN) is trading at is $84.18, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.